We advised the underwriters in connection with the IPO and Nasdaq listing

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,350,000 shares of common stock of RxSight, Inc. at $16.00 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol “RXST.”

Based in Aliso Viejo, California, RxSight is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens, RxSight Light Delivery Device and accessories, is the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Ganiatu Afolabi. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and David A. Frey. The tax team included associate Shay Moyal. Partner Adam Kaminsky and associate Melissa Esposito provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post